Regulatory controlled expression of transgenes in primates

JP2026520102APending Publication Date: 2026-06-22ASKLEPIOS BIOPHARMACEUTICAL INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ASKLEPIOS BIOPHARMACEUTICAL INC
Filing Date
2024-04-17
Publication Date
2026-06-22

AI Technical Summary

Technical Problem

Current gene therapy methods lack the ability to precisely control transgene expression levels in primates, leading to adverse outcomes such as overexpression or underexpression, which can reduce therapy efficacy or cause toxicity, and preclinical data from rodents have limited predictive power for human applications.

Method used

A method involving multiple administrations of inducers, such as artemisinin or flavonoid compounds, to regulate transgene expression in primates using inducible promoters activated by a CAR and RXR heterodimer, allowing for precise control of transgene expression levels.

Benefits of technology

Enables precise and predictable regulation of transgene expression in primates, reducing toxicity and improving therapy efficacy by maintaining optimal expression levels over time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026520102000001_ABST
    Figure 2026520102000001_ABST
Patent Text Reader

Abstract

The techniques described herein generally relate to methods and compositions for the regulated and controllable expression of transgenes in subjects, such as primate subjects.
Need to check novelty before this filing date? Find Prior Art